EMA Authorised: NutropinAq (somatropin) — Ipsen Pharma

View source ↗

Summary

EMA authorised NutropinAq (somatropin) for Turner syndrome and pituitary dwarfism, with Ipsen Pharma as MAH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pituitary Dwarfism
• Turner Syndrome

Drugs mentioned

• NutropinAq (somatropin)

Snippet

Status: Authorised. Therapeutic area: Turner Syndrome;Dwarfism, Pituitary. MAH: Ipsen Pharma. Decision date: 20/07/2023